Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter Phase Ib/2a Study of TEW-7197 (Vactosertib) Plus Weekly Paclitaxel As Second-line Treatment for Metastatic Gastric Adenocarcinoma

NCT03698825 is registered in ClinicalTrials.gov with MedPacto, Inc. as lead sponsor.

NCT NCT03698825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03698825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter Phase Ib/2a Study of TEW-7197 (Vactosertib) Plus Weekly Paclitaxel As Second-line Treatment for Metastatic Gastric Adenocarcinoma
Lead sponsor
MedPacto, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
August 15, 2018
Completion date
December 28, 2022
Enrollment
62 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic gastric cancer